과학기자재전시실 | 견적의뢰 | 미등재상품상담 | 수출입 및 제조상담 | 실험상담 | 협력업체문의
(Technical References) EPIDRM
 

 
  →  상품상세정보  

 

Technical References for Epiderm

 

 

 

732. NICOTINIC ACETYLCHOLINE RECEPTOR STIMULATION IMPAIRS EPIDERMAL PERMEABILITY BARRIER FUNCTION AND RECOVERY AND MODULATES CORNIFIED ENVELOPE PROTEINS.

Curtis1,2, B.J., Plichta1,2, J.K., Blatt1,2, H., Droho1,2, S., Griffin1,2, T.M., Radek1,2, K.A. ¹ Loyola University, Chicago, USA. ² Health Sciences Campus, Department of Surgery, Burn & Shock Trauma Institute, Maywood, IL 60153, USA. Life Sciences, 91, 1070-1076, (2012).

 

725. TOPICAL DELIVERY OF SIRNA-BASED SPHERICAL NUCLEIC ACID NANOPARTICLE CONJUGATES FOR GENE REGULATION

Zheng1,2, D., Giljohann1,2, D.A., Chen3, D.L., Massich1,2, M.D.,  Wang3, X-Q, Iordanov3, H., Mirkin1,2, C.A. and Paller3, A.S.  1Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208; 2International Institute for Nanotechnology, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208; and 3Department of Dermatology, Feinberg School of Medicine, Northwestern University, 676 North St. Clair Street, Suite 1600, Chicago, IL 60611. PNAS, 109, 30, 11975-11980,(2012).

 

719. ELUCIDATION OF XENOBIOTIC METABOLISM PATHWAYS IN HUMAN SKIN AND HUMAN SKIN MODELS BY PROTEOMIC PROFILING.

van Eijl1, S., Zhu1, Z., Cupitt1, J., Gierula1, M., Gotz2, C., Fritsche2,3, E., Edwards1, R.J. 1Centre for Pharmacology and Therapeutics, Division of Experimental Medicine, Imperial College London, London, United Kingdom, 2Leibniz Institut fur Umweltmedizinische Forschung, Heinrich-Heine-Universitat, Dusseldorf, Germany, 3 Department of Dermatology and Allergology, University Clinic RWTH, Aachen, Germany. PLoS ONE, 7, 7, (2012).

 

718. COMPARISON OF LOW AND HIGH DOSE IONISING RADIATION USING TOPOLOGICAL ANALYSIS OF GENE COEXPRESSION NETWORKS.

Ray,M., Yunis, R., Chen, X. and Rocke, D.M. Division of Biostatistics, School of Medicine, University of California, Davis, CA. USA.  BMC Genomics, 13:190 (2012).

 

715. NUCLEOTIDE EXCISION REPAIR IS REDUCED IN ORAL EPITHELIAL TISSUES COMPARED WITH SKIN.

Mitchell1, D., Paniker1, L. and Godar2, D. 1Department of Carcinogenesis, University of Texas, MD Anderson Cancer Center, Smithville, TX. 2US Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, MD. Photochem. and Photobio., 88, 1027–1032, (2012).

 

714. ENHANCED ANTIVIRAL ACTIVITY OF ACYCLOVIR LOADED INTO NANOPARTICLES.

Cavalli1, R., Donalisio2, M., Bisazza1, A., Civra2, A., Ranucci3, E., Ferruti3, P. and Lembo2, D. 1Dipartimento di Scienza e Tecnologia del Farmaco, Universita` di Torino, Torino, Italy. 2Dipartimento di Scienze Cliniche e Biologiche, Universita` di Torino, Torino, Italy. 3Dipartimento di Chmica Organica e Industriale, Universita` degli Studi di Milano, Milano, Italy. Methods in Enzymology, 509, (2012).

 

705. γ-H2AX FORMATION IN THREE-DIMENSIONAL HUMAN SKIN AND CELL MODELS FOLLOWING INVITRO EXPOSURE TO SULFUR MUSTARD.

Miller, A., Waraich, N., Clark, O., Nealley, E., Leiter, K. and Smith, W. Research Division, US Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland. Society of Toxicoloy Meeting, March 2009.

 

697. EVALUATION OF AN IN VITRO HUMAN SKIN IRRITATION TEST FOR USE WITH MEDICAL DEVICE EXTRACTS

Coleman1, K.P., Casas1, J.W., Lewerenz1, G.M., Rankin1, E.A., Willoughby2, J.A. Sr., Blakeman2, L.C. and McKim2, J.M. Jr. 1Medtonic, Inc., Minneapolis, MN, 55432 2CeeTox, Inc., Kalamazoo, MI, 49008.

 

693. CLASSIFICATION AND LABELING OF INDUSTRIAL PRODUCTS WITH EXTREME PH BY MAKING USE OF IN VITRO METHODS FOR THE ASSESSMENT OF SKIN AND EYE IRRITATION AND CORROSION IN A WEIGHT OF EVIDENCE APPROACH.

Scheel1, J., Heppenheimer2,A., Lehringer1, E., Kreutz1, J., Poth2, A., Ammann1, H., Reisinger1, K., Banduhn1, N.  1Henkel AG & Co. KGaA, Düsseldorf, Germany. 2Harlan Cytotest Cell Research GmbH, Rossdorf, Germany. Toxicology in Vitro, 25, 1435–1447 (2011).

 

690. NIACINAMIDE DIMINISHED UVB INDUCED STRESS RESPONSE IN HUMAN EPIDERMAL EQUIVALENT MODEL.

Hattori1, K., Kawamata1, T., Date2, A., Tamura1, H. 1Faculty of Pharmacy, Keio University, Tokyo, Japan, 2Kobe Technical Center, Procter and Gamble, Japan. 36th Annual Meeting of the Japanese Society for Investigative Dermatology, Abstract P11-19 (2011).

 

689. THE STATE OF NANO-SIZED TITANIUM DIOXIDE (TIO2) MAY AFFECT SUNSCREEN PERFORMANCE.

Tyner 1, K.M., Wokovich2, A.M., Godar3, D.E., Doub2,W.H. and Sadrieh 1, N.   1Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993, 2Center for Drug Evaluation and Research, Food and Drug Administration, Saint Louis, MO 63101 and 3Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD 20993, U.S.A.  International Journal of Cosmetic Science, 1–15 (2011).

 

687. COLIPA VALIDATION OF THE RECONSTRUCTED HUMAN SKIN MICRONUCLEUS ASSAY (RSMN): FURTHER PRE-VALIDATION STUDIES AND INVESTIGATIONS IN INCREASING TIME EFFICIENCY.

Fautz1, R., Quedraogo2, G., Reisinger3, K., Aardema4, M., Barnett5, B., Faquet2, B., Mun6, G., Dahl6,  E., Curren6, R., Hewitt7, N. and Pfuhler5, S. 1KPSS-Kao Professional Salon Services, Darmstadt, Germany; 2L’Oreal Life Sciences Research, Aulnay sous Bois, France; 3Henkel AG & Co KGaA, Duesseldorf, Germany; 4Bioreliance, Rockville, MD, USA, 5The Procter & Gamble Co., Cincinnati, OH, USA, 6Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA; 7Erzhausen, Germany.

 

686. THE USE OF 3D SKIN MODELS IN THE MICRONUCLEUS AND COMET ASSAYS: FURTHER PRE-VALIDATION STUDIES AND INVESTIGATIONS INTO INCREASING THROUGHPUT.

Pfuhler1, S., Quedraogo2, G., Reisinger3, K., Krul4, C., Curren5, R., Aardema6, M., Fautz7, R., Barnett1, B., Downs1, T., Reuss4, A., Faquet2, B., Mun5, G., Hewitt8, N. 1The Procter & Gamble Co., Cincinnati, OH, USA; 2L’Oreal Life Sciences Research, Aulnay sous Bois, France; 3Henkel AG & Co KGaA, Duesseldorf, Germany; 4TNO, The Netherlands; 5Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA; 6Marilyn Aardema Consulting, LLC, USA; 7KPSS-Kao Professional Salon Services, Darmstadt, Germany; 8Erzhausen, Germany.

 

684.USE OF NORMAL HUMAN 3-DIMENSIONAL (NHU-3D) TISSUE MODELS (EPIDERM™, EPIAIRWAY™) FOR NANOTOXICOLOGY APPLICATIONS.

Hayden, P., Kaluzhny, Y., Armento, A., DeLuca, J., Karetsky, V., Kubilus, J., Ayehunie, S., Kandarova, H. and Klausner, M. MatTek Corporation, Ashland, MA, USA & MatTek In Vitro Life Science Laboratories, Bratislava, Slovakia. Presented at Genetic Toxicology Association Meeting, Newark, DE, USA, September 2011.

 

683. UPDATE ON VALIDATION STATUS AND INDUSTRY UTILIZATION OF NORMAL HUMAN 3D (NHU-3D) ANIMAL ALTERNATIVE MODELS.

Kandarova, H., Klausner, M., Kubilus, J., Ayehunie, S., Hayden, P., Kaluzhny, Y., Letasiova, S., and Sheasgreen, J.  MatTek Corporation, Ashland, MA, USA and MatTek In Vitro Life Science Laboratories, Bratislava, Slovakia. Presented at 8th World Congress on Alternative and Animal Use, Montreal, Canada, 2011.

 

682. CHARACTERIZATION OF ENZYME ACTIVITIES OF CYTOCHROME P450 ENZYMES, FLAVIN-DEPENDENT MONOOXYGENASES, N-ACETYLTRANSFERASES AND UDP-GLUCURONYLTRANSFERASES IN HUMAN RECONSTRUCTED EPIDERMIS AND FULL-THICKNESS SKIN MODELS.

Jäckh1, C., Blatz1, V., Fabian1, E., Guth1, K., van Ravenzwaay1, B., Reisinger2, K., Landsiedel1, R. 1BASF SE, Experimental Toxicology and Ecology, 67056 Ludwigshafen, Germany. 2Henkel AG & Co. KGaA, 40191 Düsseldorf, Germany. Toxicology in Vitro, 25, 1209–1214 (2011).

 

680. NVC-422: TOWARDS DEVELOPING PRECLINICAL INFECTED TISSUE MODELS.

Zuck, M., Hybiske, K., Jelke, A., Debabov, D., and Anderson, M. NovaBay Pharmaceuticals, Inc., Emeryville, CA Interscience Conference on Antimicrobial Agents and Chemotheraphy (ICAAC), Boston, MA 2011

 

679. THE USE OF HUMAN 3D EPIDERMAL MODELS FOR GENOTOXICITY TESTING: RESULTS WITH THE COMET ASSAY.

Krul, C., Reus, A., Reisinger, K., Downs, T., Pfuhler, S. TNO Innovation for life.  Presented at 8th World Congress on Alternatives and Animal Use, Montreal, Canada, 2011.

 

678. INVESTIGATION OF THE BIOTRANSFORMING CAPACITY OF HUMAN RECONSTRUCTED SKIN MODELS FOR GENOTOXICITY TESTING.

Blatz1, V., Jackh1,C., Reisinger2, K., Fabian1, E., van Ravenzwaay1, B., Landsiedel1, R. 1Experimental Toxicology and Ecology, BASF SE. 67056 Ludwigshafen, Germany. 2Henkel AG & CO, KGaA, 40191 Dusseldorf, Germany.

 

677. BACTERIAL INACTIVATION OF WOUND INFECTION IN A HUMAN SKIN MODEL BY LIQUID-PHASE DISCHARGE PLASMA.

Kim, P.Y., Kim, Y-S. Koo, I.G., Jung, J.C., Kim, G.J., Choi, M.Y., Yu, Z., Collins, G.J.  Department of Electrical and Computer Engineering, Colorado State University, Fort Collins, Colorado, United States of America. PLoS ONE, 6,  8, (2011).

 

676. DEVELOPMENT OF A NEW RECONSTRUCTED HUMAN EPIDERMIS (RHE)-BASED SCREENING ASSAY FOR CONTACT ALLERGENS.

Miyazawa, M., Nukada, Y., Saito, K., Sakaguchi, H., Nishiyama, N. Kao Corporation, Tochigi, Japan.  Presented at 8th World Congress on Alternatives and Animal Use, Montreal, Canada, 2011.

 

674. RETROSPECTIVE ANALYSIS OF THE EPIDERM 3-MINUTE PREDICTION MODEL FOR ASSESSMENT OF GHS SKIN CORROSION PACKING GROUP SUB-CATEGORY 1A.

Kandarova, H., Kaluzhny, Y., Kubilus, J. Hayden, P., Sheasgreen, J. and Klausner, M.MatTek Corporation, Ashland, MA, USA MatTek In Vitro Life Science Laboratories, Bratislava, Slovakia. Presented at 8th World Congress on Alternatives and Animal Use, Montreal, Canada, 2011.

 

666. SURFACTANT-LIKE PROPERTIES OF ALKALINE EXTRACTS FROM WASTEWATER BIOSOLIDS.

Becerra, F.Y.G., Allen, D.G., Acosta, E.J.  Department of Chemical Engineering and Applied Chemistry, University of Toronto, Canada. J Surfact Deterg, 13:261–271 (2010).

 

658. EVALUATION OF XENOBIOTIC METABOLISM IN HUMAN RECONSTRUCTED SKIN MODELS FOR GENOTOXICITY TESTING.

Jackh1, C, Blatz1, V., Fabian1, E., Reisinger2 , K., van Ravenzwaay1 , B., Trappe3, S., Landsiedel1, R.  1Experimental Toxicology and Ecology, BASF SE, 67056 Ludwigshafen, Germany. 2Henkel AG & CO. KGaA, 40191 Düsseldorf, Germany.  3Federal Institute for Risk Assessment (BfR), 14195 Berlin, Germany. Presented at SOT 2011, Abstract #1005.

 

657. IN VITRO ASSESSMENT OF SKIN IRRITATION POTENTIAL OF SURFACTANT BASED FORMULATIONS USING 3-D SKIN RECONSTRUCTED TISSUES AND CYTOKINE EXPRESSION ANALYSIS.

Gandolfi1, L., Tierney1, N., Johnson1, D., Walters1, R., Fevola1, M., Gunn1, E., Martin1, K., Kong2, A., Hilberer2, A., Barnes2, N., Wilt2, N., Nash2, J.R., Inglis2, H., Raabe2, H., Costin2, G-E. 1Johnson & Johnson, Skillman, NJ, United States 2Institute for In Vitro Sciences, Inc., Gaithersburg, MD, United States. Presented at SOT 2011, Abstract #2555.

 

649. IL-18 SECRETION AS A MARKER FOR IDENTIFICATION OF CONTACT SENSITIZERS IN THE EPIDERM IN VITRO HUMAN SKIN MODEL.

Deng, W., Oldach, J., Armento, A., Ayehunie, S., Kandarova, H., Letasiova, S., Klausner, M., and Hayden, P. MatTek Corporation, Ashland, MA, USA. Presented at SOT 2011, Abstract #2571.

 

645. THE RECONSTRUCTED SKIN COMET ASSAY SHOWS GOOD INTRA- AND INTER-LABORATORY REPRODUCIBILITY: RESULTS FROM THREE LABORATORIES.

Downs1, T., Reus2,A., Reisinger3, K., Krul2, C., and Pfuhler1, S. 1Procter & Gamble Co., Cincinnati, OH, USA,  2TNO Quality of Life, Zeist, The Netherlands, 3Henkell AG & Co KgaA, Dusseldorf, Germany. Presented at SOT 2011, Abstract #341.

 

638. DYNAMIC AND PHYSICAL CLUSTERING OF GENE EXPRESSION DURING EPIDERMAL BARRIER FORMATION IN DIFFERENTIATING KERATINOCYTES.

Taylor1, J.M., Street2, T.L., Hao3, L., Copley1, R., Taylor1, M.S., Hayden4, P.J., Stolper4, G., Mott1, R., Hein2, J., Moffatt3, M.F., Cookson3, W.O.C.M. 1Wellcome Trust Centre for Human Genetics, Oxford, England, 2Oxford Centre for Gene Function, Department of Statistics, University of Oxford, Oxford, England, 3National Heart and Lung Institute, Imperial College, London, England, 4MatTek Corporation, Ashland, Massachusetts, United States of America. PLos ONE, 4, 10, (2009).

 

636. DEVELOPMENT OF A NEW IN VITRO GENETIC TOXICOLOGY MODEL USING RECONSTRUCTED HUMAN SKIN.

Curren, R.D.  Institute for In Vitro Sciences, Gaithersburg, MD, USA. Forinvitox, Stockholm, Sweden, (2009).

 

633. IN VITRO GENOTOXICITY TESTING USING THE MICRONUCLEUS ASSAY IN CELL LINES, HUMAN LYMPHOCYTES AND 3D HUMAN SKIN MODELS.

Kirsch-Volders1, M., Decordier1, I., Elhajouji1, A., Plas2, G., Aardema2, M.J. and Fenech3, M. Laboratorium voor Cellulaire Genetica, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brussels, Belgium, 1Novartis Institutes for Biomedical Research, Translational Sciences, Preclinical Safety, Genetic Toxicology and Safety Pharmacology, CH-4002 Basel, Switzerland, 2Marilyn Aardema Consulting, LLC, 5315 Oakbrook Dr., Fairfield, OH 45014, USA and 3CSIRO Food and Nutritional Sciences, Nutritional Genomics, Gate 13, Kintore Avenue, PO Box 10041, Adelaide BC, SA 5000, Australia. Mutagenesis, 26, (1), 177-184 (2011).

 

629. THE RECONSTRUCTED SKIN MICRONUCLEUS ASSAY (RSMN) IN EPIDERM™: DETAILED PROTOCOL AND HARMONIZED SCORING ATLAS.

Dahl1, E.L., Curren1, R., Barnett2, B.C., Khambatta2, Z., Reisinger3, K., Quedraogo4, G., Faquet4, B., Ginestet4, A-C., Mun1, G., Hewitt5, N.J., Carr2, G., Pfuhler2, S., Aardema6, M.J. 1Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA. 2Procter & Gamble, Miami Valley Laboratories, Cincinnati 45253, USA. 3Henkel AG & Co KGaA, Duesseldorf, Germany. 4L'Oreal Life Sciences Research, Aulnay sous Bois, France. 5SWS, Erzhausen, Germany. 6Marilyn Aardema Consulting, LLC, 5315 Oakbrook Dr., Fairfield, OH, USA. Mutation Research, Article in Press (2010).

 

622. MEETING REQUIREMENTS OF OECD TG 404 FOR IN VITRO SKIN IRRITATION TESTING: REPRODUCIBILITY OF EPIDERM SKIN IRRITATION TEST (EPIDERM-SIT) FOLLOWING ECVAM VALIDATION AND ACCEPTANCE AS A FULL REPLACEMENT METHOD.

MatTek Corporation, Ashland, MA, U.S.A. IIVS In vitro Alternatives 2010 Forum.

 

621. GENOTOXICITY TESTING USING THE NORMAL HUMAN CELL BASED 3D EPITHELIAL MODELS.

Kaluzhny, Y., Karetsky, V., DeLuca, J., Armento, A., Hayden, P., Ayehunie, S. and Klausner, M. MatTek Corporation, Ashland, MA, USA. IIVS In Vitro Alternatives Forum, October 2010.

 

616. VISUALISING FREE RADICAL INHIBITION FROM TOPICALLY APPLIED ANTIOXIDANTS.

Blenkiron1, P., Betteridge1, J., Vanoosthuyze1, K., Flood2, J. 1P&G Beauty, Egham, United Kingdom; 2P&G Beauty, Cincinnati, OH, United States. J. Am Acad Dermatol., P200, February 2007.

 

614. INVESTIGATING THE PROTECTIVE PROPERTIES OF MILK PHOSPHOLIPIDS AGAINST ULTRAVIOLET LIGHT EXPOSURE IN A SKIN EQUIVALENT MODEL.

Ashley Russell1, A., Laubscher2, A., Jimenez-Flores2, R., Laiho1, L.H. 1Biomedical Engineering Department, California Polytechnic State University, San Luis Obispo, CA USA 93407. 2Dairy Products Technology Center, California Polytechnic State University, San Luis Obispo, CA USA 93407. Proc. of SPIE, 7569, 7569Z, (2010). Proc. of SPIE, 7569, 7569Z, (2010).

 

607. TRANSCUTANEOUS IMMUNIZATION USING COMMON CHEMICALS.

Karande1, P., Arora2, A., Pham3, T.K., Stevens3, D., Wojicki3, A., Mitragotri2,3, S. 1Department of Chemical & Biological Engineering, Rensselaer Polytechnic Institute, Troy, NY 12180, United States. 2Biomolecular Science and Engineering, University of California, Santa Barbara, CA 93106, United States. 3Department of Chemical Engineering, University of California, Santa Barbara, CA 93106, United States. J. of Controlled Release, 138, 134-140, 2009.

 

606. DIFFUSION MEASUREMENTS IN EPIDERMAL TISSUES WITH FLUORESCENT RECOVERY AFTER PHOTOBLEACHING.

Cornelissen, L.H., Bronneberg, D., Oomens, C.W.J., and Baaijens, F.P.T. Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. Skin Research and Technology, 14, 462-467, 2008.

 

605. THE COLIPA SKIN METABOLISM PROJECT: DO IN VITRO ALTERNATIVES COMPRISE ADEQUATE DETOXIFICATION CAPACITIES FOR CHEMICAL TESTING IN SKIN?

Gotz2, C., Ruwiedel2, K., Pfeiffer2, R., Hubenthal2, U., Edwards2, R., Carmichael1, P., Aeby4, P., Goebel5, C., Pease1, C., Fritsche2,6, E. 1Unilever, Safety & Environmental Assurance Centre, Sharnbrook, Bedford, UK. 2Institute for Environmental Health Research (IUF gGmbH), Dusseldorf, Germany. 3Imperial College London, Hammersmith Campus, London UK. 4Procter and Gamble, Cosmital, Marly, Switzerland. 5Procter and Gamble, Darmstadt, Germany. 6Clinic of Dermatology, RWTH Aachen, Germany. Presented at IUTOX Meeting, Barcelona, Spain, 2010.

 

603. INTERNATIONAL PREVALIDATION STUDIES OF THE EPIDERM™ 3D HUMAN RECONSTRUCTED SKIN MICRONUCLEUS (RSMN) ASSAY: TRANSFERABILITY AND REPRODUCIBILITY.

Aardema1, M.J., Barnett1, B.C., Khambatta1, Z., Reisinger2, K., Ouedraogo-Arras3, G., Faquet3, B., Ginestet3, A.-C., Mun4, G.C., Dahl4, E.L., Hewitt5, N.J., Corvi6, R., Curren, R.D. 1Procter & Gamble, Miami Valley Laboratories, 11810 East Miami River Road, Cincinnati, OH 45253, USA. 2Henkel AG & Co. KGaA, Henkelstraße 67, 40589 Düsseldorf, Germany. 3L’Oreal Life Sciences Research, 1, Av Eugene Schueller 93600 Aulnay sous Bois, France. 4Institute for In Vitro Sciences (IIVS), Inc., 30 West Watkins Mill Road, Suite 100, Gaithersburg, MD 20878, USA. 5Scientific Writing Services, Wingertstrasse 25, 64390 Erzhausen, Germany. 6European Centre for the Validation of Alternative Methods (ECVAM), Institute for Health and Consumer Protection (IHCP), European Commission Joint Research Centre (JRC), 21020 Ispra, Va, Italy. Mutation Research, 701, 123-131, 2010.

 

602. INCREASED HYALURONAN PRODUCTION AND DECREASED E-CADHERIN EXPRESSION BY CYTOKINE-STIMULATED KERATINOCYTES LEAD TO SPONGIOSIS FORMATION.

Ohtani1, T., Memezawa1, A., Okuyama1, R., Sayo2, T., Sugiyama2, Y., Inoue2, S., and Aiba1, S. 1Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan. 2Kanebo Cosmetics Inc., Odawara, Japan. J. of Invest. Dermatol., advance online publication, 1 January 2009; doi:10.1038/jid.2008.394.

 

600. THE SERINE PROTEASE MARAPSIN IS EXPRESSED IN STRATIFIED SQUAMOUS EPITHELIA AND IS UP-REGULATED IN THE HYPERPROLIFERATIVE EPIDERMIS OF PSORIASIS AND REGENERATING WOUNDS.

Li1, W., Danilenko2, D.M., Bunting3, S., Ganesan1, R., Sa2, S., Ferrando2, R., Wu4, T.D., Kolumam3, G.A., Ouyang5, W. and Kirchhofer1, D.  From the Departments of 1Protein Engineering, 2Pathology, 3Tumor Biology and Angiogenesis, 4Bioinformatics, and 5Immunology, Genentech, Inc., South San Francisco, California 94080. J. of Biological Chem., 284, 1, 2009.

 

598. A ZN(LL)-GLYCINE COMPLEX SUPPRESSES UVB-INDUCED MELANIN PRODUCTION BY STIMULATING METALLOTHIONEIN EXPRESSION.

Ochiai1, Y., Kaburagi1, S., Okano1, Y., Masaki1, H., Ichihashi2, M., Funasaka3, Y. and Sakurai4, H. 1Cosmos Technical Center Co., Ltd, Tokyo, Japan. 2Sun Clinic, Sun Care Institute, Osaka, Japan. 3Division of Dermatology, Department of Clinical Molecular Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. 4Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan. International J. of Cosmetic Science, 30, 105-112, 2008.

 

595. DC DETOXDEFENSE™ STIMULATES SKIN’S OWN SOD ANTIOXIDANT PROTECTION AND DETOXIFICATION.

Distinctive Cosmetic Ingredients, LLC, South Plainfield, NJ, USA.

 

593. DERMAL PENETRATION OF PESTICIDES AND POLYCHLORINATED BIPHENYLS FROM HOUSE DUST.

Ertl1, H., Müller2, M. and Butte1, W. 1Carl-von-Ossietzky University of Oldenburg, Institute of Pure and Applied Chemistry, Working Group Prof. Butte, 26111 Oldenburg, Germany, 2Carl-von-Ossietzky University of Oldenburg, Institute of Biology and Environmental Sciences, 26111 Oldenburg, Germany.

 

590. β-GLUCOCEREBROSIDASE ACTIVITY IN MAMMALIAN STRATUM CORNEUM.

Takagi1, Y., Kriehuber2, E., Imokawa1, G., Elias2, P.M. and Holleran2, W.M. 1Biological Science laboratories, Kao Corporation, Tochigi, Japan, and 2Department of Dermatology, School of Medicine, University of California, and Dermatology Service and Research Unit, Veterans Affairs Medical Center, San Francisco, CA 94121-1598. J. Lipid Res., 40: 861–869, 1999.

 

588. PHOTOTOXICITY OF BERGAMOT OIL ASSESSED BY IN VITRO TECHNIQUES IN COMBINATION WITH HUMAN PATCH TESTS.

Kjlova1, K., Jirova1, D., Bendova1, H., Kandarova2, H., Weidenhoffer1, Z., Kolarova3, H., Liebsch2, M. 1National Reference Center for Cosmetics, National Institute of Public Health, Srobarova 48, 100 42 Prague 10, Czech Republic. 2Federal Institute for Risk Assessment (BfR), ZEBET at the BfR, Berlin, Germany. 3Medical Faculty of Palacky University, Olomouc, Czech Republic. Toxicology in Vitro, 21, 1298–1303 (2007).

 

587. SAFETY TESTING OF REMERGENT™ SKINCARE PRODUCTS.

AGI Dermatics, 205 Buffalo Avenue, Freeport, NY 11520.

 

585. ASSESSMENT OF SKIN ABSORPTION AND IRRITATION POTENTIAL OF ARACHIDONIC ACID AND GLYCERYL ARACHIDONATE USING IN VITRO DIFFUSION CELL TECHNIQUES.

Eppler1,2, A.R., Kraeling1, M.E.K., Wickett2, R.R., Bronaugh1, R.L. 1Offce of Cosmetics and Colors/Division of Cosmetics and Compliance, US Food & Drug Administration, Laurel MD, United States. 2College of Pharmacy, University of Cincinnati, Cincinnati, OH, United States. Food and Chemical Toxicology, 45, 2109–2117 (2007).

 

583. NON-ANIMAL METHODS FOR TOXICITY TESTING: THE WAY FORWARD FOR IN VITRO SKIN IRRITATION TESTING.

Hayden, P. MatTek Corporation. AltTox.org.

 

582. NON-ANIMAL METHODS FOR TOXICITY TESTING: SKIN IRRITATION/CORROSION.

AltTox.org, 2008

 

580. NON-ANIMAL METHODS FOR TOXICITY TESTING: EMERGING RESEARCH, METHODS & POLICIES.

AltTox.org. 2008.

 

579. IN VITRO APPROACHES FOR PREDICTING IRRITATION POTENTIAL OF TOPICAL EXPOSURES TO THE SKIN AND EYES.

Harbell, J.W. Mary Kay, Dallas, Texas.

 

576. COMPARATIVE STUDIES ON THE BIOTRANSFORMATION OF BENZO[A]PYRENE IN HUMAN KERATINOCYTES, IN VITRO SKIN MODELS, AND SKIN EX VIVO: METABOLITE PATTERNS AS INDICATOR FOR THE METABOLIC CAPACITY OF SKIN EQUIVALENTS.

Brinkmann1, J., Hutzler1, C., Trappe1, S., Stolpmann1, K., Bock2, U., Liebsch3, M., Henkler1, F., and Luch1,3, A. 1Federal Institute for Risk Assessment (BfR). Thielallee 88-92, 14195 Berlin. 2Across Barriers GmbH, Science Park 1, 66123 Saarbrucken. 3BfR-ZEBET, Center for Alternatives to Animal Testing, Diedersdorfer Weg 1, 12277 Berlin. Presented at: Skin In Vitro 2010 conference, Frankfurt, Germany, June 08 - June 09, 2010.

 

575. A TIERED APPROACH TO THE USE OF ALTERNATIVES TO ANIMAL TESTING FOR THE SAFETY ASSESSMENT OF COSMETICS: GENOTOXICITY. A COLIPA ANALYSIS.

Pfuhler1, S., Kirst2, A., Aardema1, M., Banduhn3, N., Goebel4, C., Araki5, D., Costabel-Farkas6, M., Dufour7, E., Fautz2, R., Harvey8, J., Hewitt9, N.J., Hibatallah10, J., Carmichael11, P., Macfarlane11, M., Reisinger3, K., Rowland12, J., Schellauf13, F., Schepky14, A., Scheel3, J. 1Procter & Gamble, Miami Valley Laboratories, 11810 East Miami River Road, Cincinnati, 45253 OH, USA. 2KPSS – Kao Professional Salon Services GmbH, Pfungstaedter Strasse 92-100, 64297 Darmstadt, Germany. 3Henkel AG & Co. KGaA, Henkelstraße 67, 40589 Düsseldorf, Germany. 4Procter & Gamble, Darmstadt Innovation Center, Berliner Allee 65, 64274 Darmstadt, Germany. 5Kanebo Cosmetics, 89/91 Rue du Faubourg St Honoré, 75008 Paris, France. 6Johnson & Johnson GmbH, Johnson&Johnson-Platz 2, D-41470 Neuss, Germany. 7L’Oreal, River Plaza 25-29, quai Aulagnier 92600 Asnières-sur-Seine, France. 8GlaxoSmithKline R&D, Ware, Hertfordshire, UK.9Scientific Writing Services, Wingertstrasse 25, 64390 Erzhausen, Germany. 10Chanel Parfums Beaute 135, Avenue Charles de Gaulle, 92525 Neuilly sur Seine, France. 11Unilever, Colworth Science Park, Sharnbrook, Bedford MK44 1LQ, UK. 12GlaxoSmithKline Consumer HealthCare R&D, Weybridge, Surrey KT13 ODE, UK. 13COLIPA, Avenue Herrmann Debroux 15A, B-1160 Auderghem, Brussels, Belgium. 14Beiersdorf AG, BF 682, Unnastrasse 48, 20245 Hamburg, Germany. Regulatory Toxicol. and Pharmacol., 57, 315-324, (2010).

 

574. EFFECTS OF GALACTOMYCES FERMENT FILTRATE ON EPIDERMAL BARRIER MARKER CASPASE-14 IN HUMAN SKIN CELLS.

Hattori1, K., Date2, A., Nakajima2, A., Ishida2, K., Yan2, X., Yoshii2, T., Tamura1, H. 1Department of Hygienic Chemistry, Faculty of Pharmacy, Keio University, Tokyo, Japan. 2P&G Beauty & Grooming, Kobe, Japan. 68th Annual Meeting of Amer. Acad. of Derm., Miami, FL, March 2010. 68th Annual Meeting of Amer. Acad. of Derm., Miami, FL, March 2010.

 

573. INHIBITION OF CRYSTALLIZATION IN DRUG-IN-ADHESIVE-TYPE TRANSDERMAL PATCHES.

Jain, P., Banga, A.J. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, 3001 Mercer University Drive, Mercer University, Atlanta, GA 30341-4155, United States. Inter. J. of Pharmaceutics, 394, 68–74, 2010.

 

569. IRRITANCY AND ALLERGIC RESPONSES INDUCED BY TOPICAL APPLICATION OF ORTHO-PHTHALALDEHYDE.

Anderson, S.E., Umbright, C., Sellamuthu, R., Fluharty, K., Kashon, M., Franko, J., Jackson, L.G., Johnson, V.J. and Joseph, P. Health Effects Laboratory Division, National Institute for Occupational Safety and Health, Morgantown, West Virginia 26505. Toxicological Sciences, 115(2), 435–443 (2010).

 

567. XENOBIOTIC METABOLISM GENE EXPRESSION IN THE EPIDERM™ IN VITRO 3D HUMAN EPIDERMIS MODEL COMPARED TO HUMAN SKIN.

Hu1, T., Khambatta1, Z.S., Hayden2, P.J., Bolmarcich2, J., Binder1, R.L., Robinson1, M.K., Carr1, G.J., Tiesman1, J.P., Jarrold1, B.B., Osborne1, R., Reichling1, T.D., Nemeth1, S.T., Aardema1, M.J. 1The Procter and Gamble Company, Miami Valley Innovation Center, P.O. Box 538707, Cincinnati, OH 45253, USA. 2MatTek Corporation, 200 Homer Ave., Ashland, MA 01721, USA. Toxicol. In Vitro (2010), doi:10.1016/j.tiv.2010.03.013.

 

566. EVALUATION OF IN VITRO MODELS FOR REACH TOXICITY TESTING: INDUCIBILITY OF XENOBIOTIC METABOLIZING ENZYME (XME) ACTIVITY IN IN VITRO HUMAN AIRWAY (EPIAIRWAY™) AND EPIDERMAL (EPIDERM™) MODELS.

Bolmarcich1, J., Zhao2, G., Morgan2, L., Jackson, Jr.1, G.R., Klausner1, M., Falzareno2, T. and Hayden1, P.J. 1MatTek Corporation, Ashland, Massachusetts, USA. 2Tandem Labs, Woburn, Massachusetts, USA. Presented at 49th Annual SOT Meeting, Salt Lake City, Utah (2010).

 

565. FURTHER DEVELOPMENT OF AN EPIDERM™ IN VITRO SKIN IRRITATION TEST FOR THE GLOBALLY HARMONIZED SYSTEM (GHS-SIT) OF CLASSIFICATION AND LABELING OF CHEMICALS.

Armento, A., Kandarova, H., Klausner, M. and Hayden, P.J. MatTek Corporation, Ashland, Massachusetts, USA. Presented at 49th Annual SOT Meeting, Salt Lake City, Utah (2010).

 

561. NON-ANIMAL APPROACHES FOR CONSUMER SAFETY RISK ASSESSMENTS: UNILEVER'S SCIENTIFIC RESEARCH PROGRAMME.

Carmichael, P., Davies, M., Dent, M., Fentem, J., Fletcher, S., Gilmour, N., MacKay, C., Maxwell, G., Merolla, L., Pease, C., Reynolds, F., and Westmoreland, C. Safety & Environmental Assurance Centre (SEAC), Unilever, Colworth Science Park, Sharnbrook, Bedford, UK. ATLA, 37, 595–610, (2009).

 

559. IN VITRO SKIN IRRITATION TESTING: IMPROVING THE SENSITIVITY OF THE EPIDERM SKIN IRRITATION TEST PROTOCOL.

Kandárová, H., Hayden, P., Klausner, M., Kubilus, J., Kearney, P., and Sheasgreen, J. MatTek Corporation, Ashland, MA, USA. ATLA, 37, 671–689, 2009.

 

558. THE MATTEK STORY - HOW THE THREE Rs PRINCIPLES LED TO 3-D TISSUE SUCCESS!

Sheasgreen, J., Klausner, M., Kandárová, H., and Ingalls, D. MatTek Corporation, Ashland, MA, USA. ATLA, 37, 611–622, (2009).

 

557. INFLAMMATORY ACTIVITY OF PARTHENOLIDE-DEPLETED FEVERFEW (TANACETUM PARTHENIUM).

Sur1, R., Martin1, K., Liebel1, F., Lyte1, P., Shapiro1, S., and Southall2, M. 1Preclinical Pharmacology, Johnson and Johnson Skin Research Center, CPPW, a unit of Johnson & Johnson Consumer Companies, Inc., Skillman, NJ. 2Johnson & Johnson Consumer & Personal Products Worldwide, Skillman, NJ. Inflammopharmacology, 17, 42-49 (2009).

 

556. ASSESSMENT OF DERMAL TOXICITY OF NANOSILICA USING CULTURED KERATINOCYTES, A HUMAN SKIN EQUIVALENT MODEL AND AN IN VIVO MODEL.

Park1, Y-H., Kim1, J.N., Jeong1, S.H., Choi1, J.E., Lee2, S-H., Choi1, B.H., Lee3, J.P., Sohn3, K.H., Park3, K.L., Kim2, M-K., Son1, S.W. 1Laboratory of Cell Signaling and Nanomedicine, Department of Dermatology and Division of Brain Korea 21 Project for Biomedical Science, Korea University College of Medicine, Seoul, South Korea. 2Department of Biochemistry & Molecular Biology, Korea University College of Medicine, Seoul, South Korea. 3National Institute of Toxicological Research, Seoul, South Korea. Toxicology, 267, 178–181, (2010).

 

554. REGULATION OF APOPTOSIS BY P53 IN UV-IRRADIATED HUMAN EPIDERMIS, PSORIATIC PLAQUES AND SENESCENT KERATINOCYTES.

Qin1,2, J-Z., Chaturvedi1,2, V., Denning1, M.F., Bacon1, P., Panella1, J., Choubey2, D., and Nickoloff1, B.J. 1Department of Pathology, Loyola University Medical Center, Illinois, USA; 2Department of Radiation Oncology, Loyola University Medical Center, Illinois, USA. Oncogene, 21, 2991-3002, (2002).

 

550. IMPROVING GENOTOXICITY TESTING: COMET ASSAY WITH 3D SKIN MODELS.

Pfuhler7, S., Krul4, C., Ouédraogo5, G., Reus4, A., Reisinger1, K., Zeller7, A., Carmichael8, P., Corvi2, R., Hewitt3, N., Aardema9, M., Diembeck10, W., Fautz11, R, Harvey12, J., Latil13, A., Marrec-Fairley6, M. 1Henkel AG & Co KgaA, Duesseldorf, Germany; 2EC/JRC/ECVAM, Ispra, Italy; 3Erzhausen, Germany; 4TNO Quality of Life, Zeist, The Netherlands; 5L’Oréal, Aulnay-sous-Bois, France; 6COLIPA, Brussels, Belgium; 7Procter & Gamble - Cosmital SA, Marly, Switzerland ; 8Unilever, Sharnbrook, UK; 9The Procter & Gamble Co., Cincinnati, OH, USA; 10Beiersdorf AG, Hamburg, Germany; 11KPSS-Kao Professional Salon Services, Darmstadt, Germany; 12GSK, Ware, UK; 13Pierre Fabre, France. Presented at 7th World Congress on Alternatives to Animal Testing, Rome (2009).

 

545. COLIPA VALIDATION OF THE RECONSTRUCTED HUMAN SKIN MICRONUCLEUS ASSAY (RSMN): A NOVEL MICRONUCLEUS ASSAY IN A 3D HUMAN SKIN MODEL.

Aardema1, M., Khambatta1, Z., Barnett1, B., Reisinger, K., Ouedraogo3, G., Faquet3, B., Ginestet3, A.C., Mun4, G., Dahl4, E., Curren4, R., Carmichael5, P., Diembeck6, W., Fautz7, R., Harvey8, J., Hewitt9, N., Latil10, A., Pfuhler11, S., Marrec-Fairley12, M. 1The Procter & Gamble Co., Cincinnati, OH, USA; 2Henkel AG & Co KGaA, Duesseldorf, Germany; 3L’Oreal Life Sciences Research, Aulnay sous Bois, France; 4Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA; 5Unilever, Sharnbrook UK; 6Beiersdorf AG, Hamburg, Germany; 7KPSS - Kao Professional Salon Services, Darmstadt, Germany; 8GSK, Ware, UK; 9Erzhausen, Germany; 10Pierre Fabre, Toulouse, France; 11The Procter & Gamble Co., Marly, Switzerland; 12COLIPA, Brussels, Belgium. Presented at 7th World Congress on Alternatives to Animal Testing, Rome (2009).(See TR 603.)

 

543. RETAINING CELL INTEGRITY DURING ORGANOTYPIC MODEL VIABILITY ASSAYS: ALTERNATIVES TO MTT.

Kavanagh1, C.R., Crawford1, L.J., Sawicka3, K.M., Simon1,2, S.R., and Roemer1,2, E.J. Departments of 1Pathology, 2Biochemistry and Cell Biology and 3BioMedical Engineering, SUNY Stony Brook, Stony Brook, NY, 11794. Presented at Society of In Vitro Biol. Meeting, Charleston, SC, June 2009.

 

542. VALIDATING MTS AS AN ALTERNATIVE VIABILITY ASSAY TO MTT ON THE HUMAN 3-D TISSUE MODELS, EPIAIRWAY AND EPIDERM.

Kavanagh1, C.R., Crawford1, L.J., Simon1,2, S.R. and Roemer1,2, E.J. Departments of 1Pathology, and 2Biochemistry and Cell Biology, SUNY Stony Brook, Stony Brook, NY, 11794. Presented at Society of In Vitro Biol. Meeting, Charleston, SC, June 2009.

 

541. REGULATION OF TIGHT JUNCTION PERMEABILITY BY SODIUM CAPRATE IN HUMAN KERATINOCYTES AND RECONSTRUCTED EPIDERMIS.

Kurasawa1, M., Kuroda1, S., Kida1, N., Murata2, M., Oba1, A., Yamamoto1, T., Sasaki2, H. 1Pola Chemical Industries Inc., 560 Kashio-cho, Totsuka-ku, Yokohama 244-0812, Japan. 2Department of Molecular Cell Biology, Institute of DNA Medicine, The Jikei University School of Medicine, 3-35-8 Nishishinbashi, Minato-ku, Tokyo 105-8461, Japan. Biochem. Biophys. Res. Commun., 381, 171-175 (2009).

 

539. ANTIOXIDANT CAPACITY OF 3D HUMAN SKIN EPIDERM MODEL: EFFECTS ON SKIN MOISTURIZERS.

Grazul-Bilska1,2, A.T., Bilski1,2, J.J., Redmer1,2, D.A., Reynolds1,2, L.P., Abdullah3,4, K.M. and Abdullah3,4, A. 1Department of Animal Sciences, 2Cell Biology Center, North Dakota State University, Fargo. 3Department of Surgery, School of Medicine, University of North Dakota, Grand Forks and 4Plastic Surgery Institute, Fargo, ND, USA. Inter. J. of Cosmetic Science, 31, 201-208, (2009).

 

537. ANALYSIS OF IONIZING RADIATION-INDUCED DNA DAMAGE AND REPAIR IN THREE-DIMENSIONAL HUMAN SKIN MODEL SYSTEM.

Su, Y., Meador, J.S., Geard, C.R., and Balajee, A.S. Center for Radiological Research, Department of Radiation Oncology, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA. Experimental Dermatology, 1600-1625, (2009).

 

536. THE TRANSPORT PROFILE OF CYTOKINES IN EPIDERMAL EQUIVALENTS SUBJECTED TO MECHANICAL LOADING.

Cornelissen1, L.H., Bronneberg1, D., Bader1,2, D.L., Baaijens1, F.P.T., and Oomens1, C.W.J. 1Department of Biomedical Engineering, Laboratory for Biomechanics and Tissue Engineering, Eindhoven University of Technology, Building W-hoog 4.11, P.O. Box 513, 5600 MB Eindhoven, The Netherlands. 2School of Engineering and Material Science, Queen Mary, University of London, London, UK. Annals of Biomedical Engineering, 37, 5, 1007–1018 (2009).

 

533. EYE AND SKIN IRRITATION IN 3-D HUMAN TISSUE CONSTRUCTS USING MTT AND ATP ENDPOINTS.

Raabe2, H., Burdick1, J., Hanlon2, E., Hilberer2, A., Hyder2, M., Inglis2, H., Kong2, A., Majewski1, S., McNamara1, M., Mun2, G., Nash2, J., Wilt2, N. 1Beauty Avenues, Reynoldsburg, OH, USA. 2Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA. VII World Congress on Alternatives & Animal Use in the life Sciences, Rome, Italy, Sept 1, 2009.

 

531. ALTERNATIVE METHODS FOR PHOTOTOXICITY TEST USING RECONSTRUCTED HUMAN SKIN MODEL.

Sohn, S., Ju3, J.H., Son1, K.H., Lee3, J.P., Kim, J., Lim, C.H., Hong, S.K., Kwon, T.R., Chang, M., Kim2, D.S., Yoon3, H.S., Park2, K.L. Toxicological Evaluation and Research Department, 1Pharmaceuticals and Medical Devices Research Department, 2Center for Drug Development Assistance, National Institute of Food and Drug Safety Evaluation, 3KFDA. Altex, Vol 26, Spec. Issue, p. 136 (2009).

 

528. AN IN VITRO SKIN IRRITATION TEST (SIT) USING THE EPIDERM RECONSTRUCTED HUMAN EPIDERMAL (RHE) MODEL. (VIDEO Protocol)

(VIDEO Protocol) Kandarova, H., Hayden, P., Klausner, M., Kubilus, J., Sheasgreen, J. MatTek Corp., Ashland, MA (USA). JoVE. 29. www.jove.com/index/details.stp, doi: 10.3791/1366 (2009).

 

520. EFFECT OF SIZE AT THE NANOSCALE AND BILAYER RIGIDITY ON SKIN DIFFUSION OF LIPOSOMES.

Babu1, S., Fan1, C., Stepanskiy1, L., Uitto2, J., Papazoglou1, E. 1School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, Pennsylvania. 2Department of Dermatology and Cutaneous Biology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania. Journal of Biomedical Materials Research, Part A (2008).

 

517. DERMAL PENETRATION AND METABOLISM OF p-AMINOPHENOL AND p-PHENYLENEDIAMINE: APPLICATION OF THE EPIDERM HUMAN RECONSTRUCTED EPIDERMIS MODEL.

Hua, T., Baileya, R.E., Morralla, S.W., Aardemaa, M.J., Stanleyb, L.A., Skarec, J.A. aThe Procter & Gamble Company, Miami Valley Innovation Center, Cincinnati, OH, 45253, US. bConsultant in Investigative Toxicology, P.O. Box 29225, St. Andrews, Fife, KY16 9WS, UK. cThe Procter & Gamble Company, Sharon Woods Technical Center, Cincinnati, OH, 45241, US. Toxicology Letters, 188, 119–129, 2009.

 

515. FOLLOW-UP VALIDATION OF THE EPIDERM SKIN IRRITATION TEST (SIT): RESULTS OF A MULTI-CENTRE STUDY OF TWENTY REFERENCE TEST SUBSTANCES.

Liebsch1, M., Gamer2, A.O., Curren3, R.D., Frank4, J., Genschow1, E., Tharmann1, J., Remmele2, M., Bauer2, B., Raabe3, H., Barnes3, N., Hilberer3, A., Wilt3, N., Lornejad-Schäfer4, M.R., Schäfer4, C., Hayden5, P. and Kandárová5, H. 1Unit 37 at the BfR (ZEBET) - Federal Institute for Risk Assessment, Berlin, Germany, 2BASF SE - Experimentelle Toxikologie und Oekologie, Ludwigshafen, Germany. 3Institute for In Vitro Sciences, Inc., Gaithersburg, Maryland, USA, 4Centre for Alternative and Complementary Methods to Animal Testing (zet–LSL), Linz, Austria, 5MatTek Corporation, Ashland, Massachusetts, USA. Presented at SOT Expo 2009, Baltimore, MD.

 

512. FURTHER DEVELOPMENT OF THE EPIDERM 3D RECONSTRUCTED HUMAN SKIN MICRONUCLEUS (RSMN) ASSAY.

Muna, G.C., Aardemab, M.J., Hub, T., Barnettc, B., Kaluzhnyd, Y., Klausnerd, M., Karetskyd, V., Dahla, E.L., Currena, R.D. aInstitute for In Vitro Sciences Inc., 30 W. Watkins Mill Road, Suite 100, Gaithersburg, MD 20878, USA. bThe Procter & Gamble Co., P.O. Box 538707, Cincinnati, OH 45253, USA. cAdvanced Testing Laboratory, 6954 Cornell Road, Suite 200, Cincinnati, OH 45242, USA. dMatTek Corp., 200 Homer Ave., Ashland, MA 01721, USA. Mutat. Res., 673, 92-99, (2009).

 

511. INTRALABORATORY AND INTERLABORATORY EVALUATION OF THE EPIDERM 3D HUMAN RECONSTRUCTED SKIN MICRONUCLEUS (RSMN) ASSAY.

Hua, T., Kaluzhnyb, Y., Munc, G.C., Barnettd, B., Karetskyb, V., Wiltc, N., Klausnerb, M., Currenc, R.D., Aardemaa, M.J. aThe Procter & Gamble Co., P.O. Box 538707, Cincinnati, OH 45253, United States bMatTek Corporation, 200 Homer Avenue, Ashland, MA 01721, United States, cInstitute for In Vitro Sciences, Inc., 30 West Watkins Mill Road, Suite 100, Gaithersburg, MD 20878, United States, dAdvanced Testing Laboratory, 6954 Cornell Road, Suite 200, Cincinnati, OH 45242, United States. Mutat. Res., 673, 100-108 (2009).

 

505. EVALUATION OF PRO-INFLAMMATORY BIOMARKERS OF IRRITATION IN HUMAN SKIN MODEL USING MULTIPLEXED IMMUNOASSAY.

Izbicka1, E., Yee2, B., Zhang2, A., Streeper1, R.T. 1BTNS LLC, San Antonio, TX, USA and 2Panomics Inc., Fremont, CA, USA.

 

501. INHIBITING THE EFFECTS OF OXIDATIVE STRESS VIA TOPICALLY APPLIED ANTIOXIDANT FORMULATIONS.

Betteridge1, J.W., Blenkiron1, P., Flood2, J., Johnson2, M., Sun2, Y., Zeller3, A., Zhu2, C. 1P&G Beauty, Egham, UK; 2Cincinnati, Ohio, USA; 3Marly, Switzerland.

 

499. LINKER-BASED LECITHIN MICROEMULSIONS FOR TRANSDERMAL DELIVERY OF LIDOCAINE.

Yuan, J.S., Ansari, M., Samaan, M., Acosta, E.J. University of Toronto, Department of Chemical Engineering and Applied Chemistry, 200 College St., Toronto, ON, Canada M5S 3E5. International J. of Pharmaceuticals, 349, 130-143, (2008).

 

496. THE USE OF RECONSTRUCTED HUMAN EPIDERMIS FOR SKIN ABSORPTION TESTING: RESULTS OF THE VALIDATION STUDY.

Schäfer-Korting1, M., Bock2, U., Diembeck3, W., Düsing3, H-J., Gamer4, A., Haltner-Ukomadu2, E., Hoffmann5, C., Kaca2, M., Kamp4, H., Kersen6, S., Kietzmann7, M., Korting8, H.C., Krächter9, H-U., Lehr10, C-M., Liebsch11, M., Mehling9, A., Müller-Goymann5, C., Netzlaff10, F., Niedorf7, F., Rübbelke8, M.K., Schäfer10, U., Schmidt11, E., Schreiber1, S., Spielmann11, H., Vuia1, A., and Weimer6, M. 1Freie Universität Berlin, Institut für Pharmazie, Berlin, Germany; 2Across Barriers GmbH, Saarbrücken, Germany; 3Beiersdorf AG, Hamburg, Germany; 4BASF Aktiengesellschaft, Experimental Toxicology & Ecology, Ludwigshafen, Germany; 5Technische Universität Carolo-Wilhelmina zu Braunschweig, Institut für Pharmazeutische Technologie, Braunschweig, Germany; 6Fraunhofer Institut für Grenzflächen- & Bioverfahrenstechnik, Stuttgart, Germany; 7Stiftung Tierärztliche Hochschule Hannover, Institut für Pharmakologie, Toxikologie & Pharmazie, Hannover, Germany; 8Ludwig-Maximilians-Universität München, Klinik & Poliklinik für Dermatologie & Allergologie, Munich, Germany; 9Cognis Deutschland GmbH & Co. KG, Düsseldorf, Germany; 10Universität des Saarlandes, Biopharmazie & Pharmazeutische Technologie, Saarbrücken, Germany; 11Zentralstelle zur Erfassung & Bewertung von Ersatz- & Ergänzungsmethoden zum Tierversuch (ZEBET) am Bundesinstitut für Risikobewertung, Berlin, Germany. ATLA, 36, 161-187 (2008).

 

495. RECONSTRUCTED EPIDERMIS AND FULL-THICKNESS SKIN FOR ABSORPTION TESTING: INFLUENCE OF THE VEHICLES USED ON STEROID

 

  

 

 

 

www.MatTek.co.kr